Literature DB >> 21051950

βTrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit.

Yann Thomas1, Olivier Coux, Véronique Baldin.   

Abstract

The dual-specificity phosphatase CDC25B, a key regulator of CDK/Cyclin complexes, is considered as the starter of mitosis. It is an unstable protein, degraded by the proteasome, but often overexpressed in various human cancers. Based on experiments carried out in Xenopus eggs, and on video microscopy studies in mammalian cells, it has been proposed that human CDC25B degradation is dependent of the F-box protein βTrCp, but the involvement of this latter protein was not formally demonstrated yet. Here, we show that indeed, in mammalian cells, βTrCp participates to CDC25B turnover, and is required for the complete degradation of CDC25B at the metaphase-anaphase transition. Using a stabilized mutant of CDC25B, which cannot interact anymore with βTrCp, we further show that, during late phases of mitosis, reduced degradation of CDC25B leads to an extended window of expression of the protein, which in turn induces a delay in mitosis exit and entails mitotic defects such as chromosomes missegregation. These findings show that a dysfunction in the rapid and precisely controlled degradation of CDC25B at the metaphase-anaphase transition is sufficient to cause genomic instability and suggest that, in human tissues, pathologic stabilization or untimed expression of CDC25B could contribute to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051950     DOI: 10.4161/cc.9.21.13593

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  8 in total

1.  Cdc25 phosphatases: differential regulation by ubiquitin-mediated proteolysis.

Authors:  Lauren M Young; Michele Pagano
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

2.  RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

3.  p53 and p16(INK4A) independent induction of senescence by chromatin-dependent alteration of S-phase progression.

Authors:  Alexandre Prieur; Emilie Besnard; Amélie Babled; Jean-Marc Lemaitre
Journal:  Nat Commun       Date:  2011-09-13       Impact factor: 14.919

4.  Resistance to anti-microtubule drug-induced cell death is determined by regulation of BimEL expression.

Authors:  Weimei Ruan; Gireedhar Venkatachalam; Radoslaw Mikolaj Sobota; Liyan Chen; Loo Chien Wang; Alena Jacobson; Kathirvel Paramasivam; Uttam Surana
Journal:  Oncogene       Date:  2019-02-15       Impact factor: 9.867

5.  The E3 ubiquitin ligase APC/CCdh1 degrades MCPH1 after MCPH1-βTrCP2-Cdc25A-mediated mitotic entry to ensure neurogenesis.

Authors:  Xiaoqian Liu; Wen Zong; Tangliang Li; Yujun Wang; Xingzhi Xu; Zhong-Wei Zhou; Zhao-Qi Wang
Journal:  EMBO J       Date:  2017-11-17       Impact factor: 11.598

6.  Kizuna is a novel mitotic substrate for CDC25B phosphatase.

Authors:  Yann Thomas; Marion Peter; Francisca Mechali; Jean-Marie Blanchard; Olivier Coux; Véronique Baldin
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.

Authors:  Khaoula Ben Younes; Simon Body; Élodie Costé; Pierre-Julien Viailly; Hadjer Miloudi; Clémence Coudre; Fabrice Jardin; Fatma Ben Aissa-Fennira; Brigitte Sola
Journal:  BMC Cancer       Date:  2017-08-10       Impact factor: 4.430

8.  The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.

Authors:  Sara Canovas Nunes; Martina Manzoni; Marco Pizzi; Elisa Mandato; Marilena Carrino; Laura Quotti Tubi; Renato Zambello; Fausto Adami; Andrea Visentin; Gregorio Barilà; Livio Trentin; Sabrina Manni; Antonino Neri; Gianpietro Semenzato; Francesco Piazza
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.